Table 2.
Baseline characteristics of the enrolled patients in the included studies
| ID | Age, mean (SD), EID/SID | Male/Female, (%/%) | EID/SID durations | Follow-up duration | JCV ( +), n | Prior use of DMTs, n (%) | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| EID | SID | Interval duration | Mean treatment duration | EID | SID | EID | SID | |||
| Bomprezzi [33] | 41(10)/41(11) | 26/74 | 28/72 | 6–8/4 W | Minimum 6 M | 6 M | 84 | 150 | – | – |
| Butzkueven [23] | 39.9 (9.55)/40.6 (9.4) | 32.9/67.1 | 32.9/67.1 | 6/4 W | 52.32/52.92 M | 2 Years | 74 | 68 | – | – |
| Chisari [34] | 42.3(13.4)/41.6(11.5) | 38.5/61.5 | 39.9/60.1 | 39.8/30.8 D | – | 12–24 M | 31 | 245 | 296 (35.3) | 326 (26) |
| De Mercanti [35] | 34.4 (9.8)/34.9 (10.7) | – | – | 42.2/32.2 D | 32/24.64 M | 6-12-24 M | 66 | 66 | – | – |
| Foley [4] | 40·9 (9·66) /40·3 (9·94) | 30/70 | 27/73 | 6/4 W | 48/48 M | 24-48-72 W | 52 | 64 | 184 (74) | 175 (72) |
| Jeantin [39] | 24.93 (7.83) | 42.1/57.9 | 6 W | 58.17 M | 139.1 M | – | – | – | – | |
| Pelle [40] | 39.3 (9.7)/40.2 (10.6) | 25/75 | 21/79 | > 6W | – | 12 M | 19 | 14 | – | – |
| Riancho [36] | 43.41 (10.71)/38.97 (11.1) | 13/87 | 8/4 W | 76.68/51.1 M | 7 Years | 32 | – | 25(64) | ||
| Ryerson [37] | 45.59 (11.67)/45.48 (11.48) | 27/73 | 30/70 | 7-8W, 5D/4W, 3D-6W, 6D/4W | – | – | 563 | 540 | 152(17) | 1296(12) |
| Ryerson [17] (primary) | 42.9 (11.3)/44.0 (11.0) | 31/69 | 33/67 | 36.7/30 D | 59.9/47.77 M | 5 Years | 1,988 | 13٫132 | 95 (5) | 689 (5) |
| Ryerson [17] (secondary) | 43.0 (11.2)/43.9 (11.4) | 31/69 | 34/66 | 35/29.8 D | 53.56/29.02 M | 3٫331 | 15٫424 | 175 (5) | 799 (5) | |
| Ryerson [17] (tertiary) | 42.0 (11.4)/43.9 (11.6) | 34/66 | 33/67 | 43/30.5 D | 44/25.04 M | 815 | 23٫168 | 49 (6) | 1,310 (6) | |
| Ryerson [32] | 42.24(10.3)/42.48(10.33) | 28/72 | 30/70 | 6/4 W | – | 24 W | – | – | – | – |
| Trojano [21] | 38.7 (8.43)/38.4 (7.84 | 28.8/71.2 | 27.8/72.2 | 12/4 W | 3.1/3.2 Years | 72 W | – | – | – | – |
| Van Kempen [38] | 40.7 (10.4)/41.6 (10.2) | 25/75 | 40/60 | 5–7/4 W | 4/5 Years | 12 M | 17 | 3 | – | – |
| Yamout [22] | 33.76 (10.93) | 22.4/77.6 | ≥ 5/4 W | 11.83/15.45 M | 6–12 M | 38 | 75 (88.2) | |||
EID extended interval dosing, SID standard interval dosing, JCV John Cunningham virus, DMT disease-modifying therapy, D days, M months, Y years